tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Parotitis D010309 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Connor A et al. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. 2012 Transplantation pmid:23318306
Plock JA et al. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. 2015 Transplantation pmid:26102613
Stevens RB et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. 2008 Transplantation pmid:18497677
Gurk-Turner C et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. 2008 Transplantation pmid:18497682
Khanafer A et al. Increased nitric oxide production during acute rejection in kidney transplantation: a useful marker to aid in the diagnosis of rejection. 2007 Transplantation pmid:17876269
Qi S et al. Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. 2003 Transplantation pmid:12717189
Singh N et al. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. 2000 Transplantation pmid:10708096
Haririan A et al. Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. 2003 Transplantation pmid:12717201
Gonwa T et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. 2003 Transplantation pmid:12717205
Arns W et al. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. 2017 Transplantation pmid:28658202
Taber DJ et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. 2017 Transplantation pmid:28658199
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Yun J et al. Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. 2010 Transplantation pmid:20559109
Han DH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. 2010 Transplantation pmid:20562737
Ashokkumar C et al. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. 2011 Transplantation pmid:21747326
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Cosio FG et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. 2007 Transplantation pmid:17318073
Budde K et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. 2007 Transplantation pmid:17318074
Stegall MD et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. 1997 Transplantation pmid:9422404
Shield CF et al. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9422413
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Sampaio MS et al. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. 2012 Transplantation pmid:22129761
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Shibutani S et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. 2005 Transplantation pmid:15849542
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Tory R et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. 2009 Transplantation pmid:19584682
Manitpisitkul W et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. 2009 Transplantation pmid:19584685
Jain A et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. 2008 Transplantation pmid:18347534
Weiler N et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. 2010 Transplantation pmid:21048536
Winkler ME et al. Successful pregnancy in a patient after liver transplantation maintained on FK 506. 1993 Transplantation pmid:7506460
Garcia-Criado FJ et al. Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. 1998 Transplantation pmid:9798713
Mack-Shipman LR et al. Reproductive hormones after pancreas transplantation. 2000 Transplantation pmid:11063337
Chisholm MA et al. Renal transplant patient compliance with free immunosuppressive medications. 2000 Transplantation pmid:11063348
Suzuki S et al. Pure red cell aplasia induced by FK506. 1996 Transplantation pmid:8607191
Dominguez J et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. 2000 Transplantation pmid:11063349
Busuttil RW et al. General guidelines for the use of tacrolimus in adult liver transplant patients. 1996 Transplantation pmid:8607197
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Robertsen I et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. 2015 Transplantation pmid:25148382
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Nogueira JM et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. 1999 Transplantation pmid:10096529
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
Gaber AO et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. 2008 Transplantation pmid:19005398
Atkison PR et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. 1997 Transplantation pmid:9311719
Hoogduijn MJ et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. 2008 Transplantation pmid:19005411
Uryuhara K et al. Thymectomy impairs but does not uniformly abrogate long-term acceptance of semi-identical liver allograft in inbred miniature Swine temporarily treated with FK506. 2004 Transplantation pmid:15114080
Baid-Agrawal S et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. 2004 Transplantation pmid:15114085
Tzakis AG et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. 2004 Transplantation pmid:15114087
Lang T et al. Cholic acid synthesis is reduced in pediatric liver recipients during graft dysfunction due to ischemic injury and allograft rejection. 1997 Transplantation pmid:9415561
Marino IR et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. 2004 Transplantation pmid:15385809
Talbot D et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? 1997 Transplantation pmid:9415574
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
McDevitt-Potter LM et al. A multicenter experience with generic tacrolimus conversion. 2011 Transplantation pmid:21788920
Gill JS et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. 2010 Transplantation pmid:20098280
Wallia A et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. 2010 Transplantation pmid:20098286
Zhao W et al. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. 2012 Transplantation pmid:22450597
Pascual J et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 2009 Transplantation pmid:19136902
Jacobson PA et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. 2012 Transplantation pmid:22334041
Schneeberger S et al. Cytomegalovirus-related complications in human hand transplantation. 2005 Transplantation pmid:16123716
Ciancio G et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. 2005 Transplantation pmid:16123718
Vossen M et al. Bone quality in swine composite tissue allografts: effects of combination immunotherapy. 2005 Transplantation pmid:16123723
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Suzuki S et al. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. 1993 Transplantation pmid:7685932
McDiarmid SV et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. 1993 Transplantation pmid:7685933
Lauria MW et al. Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. 2010 Transplantation pmid:20061923
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Pascual M et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. 1998 Transplantation pmid:9869086
Ciancio G et al. Review of major clinical trials with mycophenolate mofetil in renal transplantation. 2005 Transplantation pmid:16251852
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Krook H et al. Immunosuppressive drugs in islet xenotransplantation: a tool for gaining further insights in the mechanisms of the rejection process. 2002 Transplantation pmid:12438951
Baran DA et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. 2002 Transplantation pmid:12438960
Blaheta RA et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. 2000 Transplantation pmid:10830246
Kasahara M et al. Role of HLA compatibility in pediatric living-related liver transplantation. 2002 Transplantation pmid:12438966
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Hudnall SD Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? 2002 Transplantation pmid:12369583
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Higgins R et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. 2009 Transplantation pmid:19300192
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Steiner RW Steroid withdrawal in kidney transplantation: the subgroup fallacy. 2011 Transplantation pmid:21336084
Jain AB et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. 2003 Transplantation pmid:14501862
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Ogawa H et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. 2002 Transplantation pmid:12151737
MacDonald AS Impact of immunosuppressive therapy on hypertension. 2000 Transplantation pmid:11152235
de Jonge H et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. 2010 Transplantation pmid:20592652
Macphee IA et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. 2005 Transplantation pmid:15729180
Shibasaki S et al. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. 2013 Transplantation pmid:23269193
Sher LS et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. 1997 Transplantation pmid:9256184
Yuzawa K and Fukao K Topical FK506 ointment for skin grafting. 1998 Transplantation pmid:9565111
Younes BS et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. 2000 Transplantation pmid:10919581
Higgins RM et al. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10919600
Cherikh WS et al. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. 2003 Transplantation pmid:12923430
Puig I Marí JM et al. Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. 2000 Transplantation pmid:10919604
Zieliński A et al. Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. 2003 Transplantation pmid:12923442
Erickson LM et al. Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. 2003 Transplantation pmid:12923448
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064